

## Commentary

# What Matters in Measuring Methamphetamine-Related Cognitive Impairments: ‘Abnormality Detection’ Versus ‘Everyday Import’?

Doris E Payer<sup>1,2</sup>, Andy C Dean<sup>3</sup> and Isabelle Boileau<sup>\*,1,2</sup>

<sup>1</sup>Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, ON, Canada; <sup>2</sup>Department of Psychiatry, University of Toronto, Toronto, ON, Canada; <sup>3</sup>UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA

Neuropsychopharmacology (2012) 37, 1081–1082; doi:10.1038/npp.2011.309

In their article ‘Is cognitive functioning impaired in methamphetamine users? A critical review,’ Hart *et al* (2011) present a provocative view of the literature on methamphetamine abuse and cognition to date, parting in their conclusions from previous reviews, which have tended to suggest that methamphetamine abuse is associated with significant cognitive abnormalities. In contrast, Hart *et al* suggest that such deficits have, in fact, only been documented in a minority of cases, and that the assumptions held by the field may have resulted from poorly worded or conflated interpretations of the evidence rather than consistent or convincing findings, to the potential detriment of treatment and policy decisions.

The concerns expressed by Hart *et al* are certainly well justified, and the article is a much-needed wake-up call to the field, as the authors flag a number of important methodology and data interpretation problems plaguing current research. Among their most poignant criticisms is the language conventionally used in interpreting and discussing findings, as studies comparing methamphetamine-abusing and control subjects often interpret any statistical difference in scores as clinically significant, resulting in overstated conclusions that often overreach the actual data. That is, studies tend to confound the definitions of statistical significance and clinically significant impairment, and assume that differences in cognitive test scores reflect a meaningful difference in real-life outcomes. In articulating this perspective and exposing the tendency of the field to report more severe deficits than are warranted by the data, the authors encourage more critical reading of previous literature and raise the bar for future studies—a service to the field as it moves forward.

At the same time, we find it curious that Hart *et al* do not offer an operational definition of what they consider clinically significant impairment, and we question their

suggestion that the majority of studies to date are of limited clinical value because test scores have not exceeded a particular normative cut-off. The authors appear to adhere to an ‘abnormality-detection’ definition, where impairment consists of a score which deviates to some degree from normative data. However, they seem to imply that this ‘abnormality-detection’ definition is synonymous with an ‘everyday import’ definition of impairment, where cognitive scores have everyday implications for real-world functioning. It should be clear that these perspectives are not the same, as a score may have relevance for everyday function and not meet a categorical cut-off for abnormality, and a score may be unrelated to everyday function even if it exceeds a particular cut-off (eg, see Silverberg and Millis (2009) for evidence that demographically normed scores can weaken real-world functional relationships).

Even within the ‘abnormality-detection’ definition of impairment, Hart *et al* do not define the degree to which a score needs to differ from demographic norms to be considered impaired. Although the authors mention a paper by Kalechstein *et al* (2003), which used stringent impairment criteria ( $>2$  SD below normative data), they do not cover an article by Rippeth *et al* (2004), which used a more liberal definition of impairment (the average of all demographically normed scores in a neuropsychological battery needed to fall approximately one-half SD below expectations—a criterion shown to maximize the sensitivity and specificity in detecting subtle cognitive deficits; see Carey *et al* (2004)). According to this definition, 40% of methamphetamine-dependent participants were classified as impaired, compared with 18% of healthy control subjects, replicating findings of subtle cognitive deficits in methamphetamine dependence, and underscoring the idea that no one cut-off value is universally accepted or optimal.

Most importantly, however, we feel that regardless of a particular cut-off chosen for impairment, it is vital that one not reify this threshold, as cognitive differences can be distressing for patients even if they do not fall some specified number of SD below the mean. For example, in criticizing an article by London *et al* (2004), which found that methamphetamine-dependent subjects had higher Beck

\*Correspondence: Dr I Boileau, Addiction Imaging Research Group, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, M5T 1R8, Canada, Tel: 416-535-8501, ext 4918, Fax: 416-979-6862, E-mail: isabelle\_boileau@camh.net

Received 4 November 2011; accepted 8 November 2011

Depression Inventory (BDI) scores than healthy control subjects, Hart *et al* argue that the clinical importance of this finding is unclear because the BDI scores do not reach a threshold for clinical depression (which may have reflected inclusion/exclusion criteria for study participation rather than patterns in the general methamphetamine-abusing population). Even so, the methamphetamine-dependent subjects in this study endorsed an average of nine depressive items, whereas healthy control subjects endorsed an average of 1. We find it difficult to believe that this difference has no relation to emotional functioning, regardless of a particular cut-off. Interestingly, Hart *et al* do not apply a given cut-off rule in concluding that acute administration of MA *enhances* cognitive functioning (they do not discuss improvement in terms of SD units from normative data). If the authors hold that improved scores may have clinical relevance on a continuous, rather than a categorical basis, we would agree.

Finally, given the authors' interest in real-world functioning, we find it noteworthy that they did not mention an article by Henry *et al* (2010), which examined measures of everyday function in abstinent methamphetamine-dependent individuals. These authors found that methamphetamine-dependent subjects performed worse on almost all indices of daily function (comprehension, finances, communication, transportation, medication management) than healthy control subjects of comparable age and education, and Wisconsin Card Sorting Test scores correlated with performance in the everyday functional domains. Perhaps one resolution to improving studies in the future is to encourage the consistent inclusion of measures of daily functioning and disability. Given the number of cognitive tests that measure specific cognitive domains but lack standardized norms, an assessment of their relationship to measures of daily function may yield useful information about clinical relevance from an 'everyday import' perspective.

Despite our criticisms, we agree with the conclusion by Hart *et al* that the field has generally over-interpreted the severity of cognitive problems in methamphetamine dependence. Our hope moving forward is that future studies will clarify their operational definitions of clinically significant impairment, and adopt appropriate strategies for data interpretation and communication of conclusions.

## DISCLOSURE

AD receives funding from the NIH (NIH grant K23 DA927734). The other authors have nothing to disclose.

## REFERENCES

- Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I *et al*, HNRC Group (2004). Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. *J Clin Exp Neuropsychol* **26**: 307–319.
- Hart CL, Marvin CB, Silver R, Smith EE (2011). Is cognitive functioning impaired in methamphetamine users? A critical review. *Neuropsychopharmacology* (in press).
- Henry BL, Minassian A, Perry W (2010). Effect of methamphetamine dependence on everyday functional ability. *Addict Behav* **35**: 593–598.
- Kalechstein AD, Newton TF, Green M (2003). Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. *Neurophysiol Clin* **15**: 215–220.
- London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J *et al* (2004). Mood disturbances and regional metabolic abnormalities in recently abstinent methamphetamine abusers. *Arch Gen Psychiatry* **61**: 73–84.
- Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R *et al* (2004). Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. *J Int Neuropsychol Soc* **10**: 1–14.
- Silverberg ND, Millis SR (2009). Impairment versus deficiency in neuropsychological assessment: Implications for ecological validity. *J Int Neuropsychol Soc* **15**: 94–102.